MarginsXMarginsX
Home › Markets › Health Care › IMCR

Immunocore Holdings plc (IMCR)

IMCR trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$28.88
-3.54% on the day
Market cap
$1.5B
Small cap
Revenue · 2025
$400.0M
+29.0% on 2024
Net income · 2025
-$35.5M
-8.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1671927/000167192726000005/0001671927-26-000005-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerIMCR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited Kingdom
IPO year2021
SEC CIK0001671927
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inUnited Kingdom

Financials · 2025

LineValue
Revenue$400.0M
Net income-$35.5M
Operating income-$45.4M
Net margin-8.9%
Operating margin-11.3%
Revenue growth+29.0%
Cash$467.7M
Total assets$1.1B
P/E (computed)Net income was not positive
P/S (computed)3.7×

Warning signs

Cash runway
590.4 months
$512.2M cash at September 30, 2026
Share count, 1 year
+2.3%
2025-10-31 to 2026-10-31 · +3.7% over 3 years
Going-concern doubt
No
10-Q filed November 6, 2026
Insider net buying, 12 months
-$5.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-06
Cash and burn$512.2M cash; operating cash flow -$2.6M a quarter.Report 2026-09-30
Shares outstanding51,681,376 (2026-10-31); 50,530,419 a year earlier; 49,820,613 three years earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte LLP, Cambridge, United KingdomPCAOB Form AP 2026-03-19
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $5.6M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$102.2M-$14.2M$20.1M$512.2MNo debt tags$429.3M10-Q 2026-11-06
Q2 2026
2026-06-30
$115.9M-$808K$15.9M$484.9MNo debt tags$430.8M10-Q 2026-08-06
Q1 2026
2026-03-31
$106.7M$13.0M-$13.8M$452.7MNo debt tags$412.8M10-Q 2026-05-06
Q4 2025
2025-12-31
$104.5M-$30.1M-$32.7M$467.7MNo debt tags$400.0M10-K 2026-02-25
Q3 2025
2025-09-30
$103.7M-$177K-$4.5M$498.4MNo debt tags$379.6M10-Q 2026-11-06
Q2 2025
2025-06-30
$98.0M-$10.3M$26.0M$487.9MNo debt tags$356.1M10-Q 2026-08-06
Q1 2025
2025-03-31
$93.9M$5.0M$435K$476.8MNo debt tags$333.6M10-Q 2026-05-06
Q4 2024
2024-12-31
$84.1M-$23.8M-$14.0M$455.7MNo debt tags$310.2M10-K 2026-02-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
427B7
424B72025-03-17
Latest annual report10-K2026-02-25
Latest quarterly / interim10-Q2026-11-06
Latest current report8-K2026-11-06
Latest proxyDEF 14A2026-04-16

Source: SEC EDGAR submissions feed, 283 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.4%
1 month+7.6%
3 months-12.5%
Year to date-13.7%
1 year-15.4%
From 52-week high-25.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
LYCALycia Therapeutics Inc.$28.61-8.30%$1.5B
MESOMesoblast Limited$12.45-6.18%$1.6B
VIRVir Biotechnology Inc.$9.58-3.82%$1.6B
NVAXNovavax Inc.$8.06-5.45%$1.3B
TSHATaysha Gene Therapies Inc.$4.06-0.98%$1.3B
ALVOAlvotech$4.41+5.13%$1.7B
WWBWindward Bio Group AG Common Shares$30.04+5.40%$1.7B
RXRXRecursion Pharmaceuticals Inc.$2.90-8.79%$1.8B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier